Ozdamar_Barish

Barish Ozdamar, PhD

Ozdamar_Barish

Barish Ozdamar, PhD

Partner

New York + 1 212 295 6537

Barish Ozdamar focuses on intellectual property disputes and IP portfolio strategy and development in the biotechnology, pharmaceutical, medical device and digital health industries. His practice spans precision medicine, gene therapy and delivery vehicles (e.g., CRISPR, AAV, and LNPs), antibodies, vaccines and other biologics, small molecule therapeutics, diagnostics (including cell-free DNA–based applications), and next-generation sequencing technologies. He also advises clients on AI-enabled healthcare technologies, including machine learning–driven diagnostics and imaging.

Dr. Ozdamar has extensive experience representing life science clients in District Court litigation, Inter Partes Review proceedings and arbitration. He also counsels clients on global transactional and diligence matters involving IP portfolio development, freedom-to-operate and landscape analysis, licensing, enforcement, and valuation and monetization in the context of mergers and acquisitions, as well as portfolio company investment strategies.

Dr. Ozdamar’s technical training is in molecular biology and genetics. Prior to his postdoctoral fellowship at Cornell University Weill Medical College, he earned his PhD at the University of Toronto, where he published research on cancer biology and molecular pathways regulating tumor metastasis. His publication record includes four authorships in Science.

Experience

  • Obtained a favorable pre-trial result for our client, a large medical device company, in connection with a gene expression platform.
  • Successful District Court representation of a leading medical diagnostic company in a matter relating to fetal genetic testing.
  • Desired outcome for multi-national pharmaceutical client faced with an infringement suit relating to antibody and screening technologies.
  • Represented and obtained a favorable pre-trial outcome for a large biotechnology company challenged by multiple generic biologic entrants against an antibody product.
  • Successful representation of a large pharmaceutical client in an ANDA litigation relating to a small-molecule anti-cancer compound.
  • Desired outcome for a large pharmaceutical client in Swiss arbitration proceedings relating to genetic screening technologies.

Recognition

  • Selected for inclusion in Best Lawyers: Ones to Watch for intellectual property law (2024–2025)
  • Canadian Institutes of Health Research Post-Doctoral Fellowship
  • Heart and Stroke Foundation of Canada Post-Doctoral Fellowship
  • Canadian Institutes of Health Research Doctoral Award

Insights & News

View all of Barish's insights & news

Credentials

  • Education

    • JD, Fordham University School of Law, 2011

    • Post-Doctoral Fellow, Biochemistry, Cornell University Weill Graduate School of Medical Sciences, 2007

    • Post-Doctoral Fellow, Cell Biology, 2006

      The Hospital for Sick Children, Toronto, Canada

    • PhD, Medical Genetics, University of Toronto, 2005

      Samuel Lunenfeld Research Institute, Mt. Sinai Hospital

    • BSc (Hons), York University, 1998

  • Admissions

    • New York

    • US Patent and Trademark Office

  • Languages

    • French

    • Turkish

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel